Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Interim analysis (n=187) shows cabozantinib significantly prolongs progression-free survival vs placebo (5.7 vs 1.9 months; HR 0.22; 96% CI 0.13–0.36). Objective response was reported in 15% on cabozantinib & 0% on placebo (p=0.028) but didn’t meet prespecified significance level

The Lancet Oncology